149 related articles for article (PubMed ID: 32787111)
1. Elucidating the Structural Requirement of Uridylpeptide Antibiotics for Antibacterial Activity.
Terasawa Y; Sataka C; Sato T; Yamamoto K; Fukushima Y; Nakajima C; Suzuki Y; Katsuyama A; Matsumaru T; Yakushiji F; Yokota SI; Ichikawa S
J Med Chem; 2020 Sep; 63(17):9803-9827. PubMed ID: 32787111
[TBL] [Abstract][Full Text] [Related]
2. Caprazamycins: Promising lead structures acting on a novel antibacterial target MraY.
Patel B; Ryan P; Makwana V; Zunk M; Rudrawar S; Grant G
Eur J Med Chem; 2019 Jun; 171():462-474. PubMed ID: 30933853
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and evaluation of cyclopentane-based muraymycin analogs targeting MraY.
Kwak SH; Lim WY; Hao A; Mashalidis EH; Kwon DY; Jeong P; Kim MJ; Lee SY; Hong J
Eur J Med Chem; 2021 Apr; 215():113272. PubMed ID: 33607457
[TBL] [Abstract][Full Text] [Related]
4. Mechanistic analysis of muraymycin analogues: a guide to the design of MraY inhibitors.
Tanino T; Al-Dabbagh B; Mengin-Lecreulx D; Bouhss A; Oyama H; Ichikawa S; Matsuda A
J Med Chem; 2011 Dec; 54(24):8421-39. PubMed ID: 22085339
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and activity of 5'-uridinyl dipeptide analogues mimicking the amino terminal peptide chain of nucleoside antibiotic mureidomycin A.
Howard NI; Bugg TD
Bioorg Med Chem; 2003 Jul; 11(14):3083-99. PubMed ID: 12818671
[TBL] [Abstract][Full Text] [Related]
6. Structural requirement of tunicamycin V for MraY inhibition.
Yamamoto K; Katsuyama A; Ichikawa S
Bioorg Med Chem; 2019 Apr; 27(8):1714-1719. PubMed ID: 30850266
[TBL] [Abstract][Full Text] [Related]
7. Structural insights into inhibition of lipid I production in bacterial cell wall synthesis.
Chung BC; Mashalidis EH; Tanino T; Kim M; Matsuda A; Hong J; Ichikawa S; Lee SY
Nature; 2016 May; 533(7604):557-560. PubMed ID: 27088606
[TBL] [Abstract][Full Text] [Related]
8. Structures of Bacterial MraY and Human GPT Provide Insights into Rational Antibiotic Design.
Mashalidis EH; Lee SY
J Mol Biol; 2020 Aug; 432(18):4946-4963. PubMed ID: 32199982
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of a MraY selective analogue of tunicamycins.
Yamamoto K; Sato T; Hikiji Y; Katsuyama A; Matsumaru T; Yakushiji F; Yokota SI; Ichikawa S
Nucleosides Nucleotides Nucleic Acids; 2020; 39(1-3):349-364. PubMed ID: 31566068
[TBL] [Abstract][Full Text] [Related]
10. Muraymycin Nucleoside Antibiotics: Structure-Activity Relationship for Variations in the Nucleoside Unit.
Heib A; Niro G; Weck SC; Koppermann S; Ducho C
Molecules; 2019 Dec; 25(1):. PubMed ID: 31861655
[TBL] [Abstract][Full Text] [Related]
11. Identification of novel inhibitors of phospho-MurNAc-pentapeptide translocase MraY from library screening: Isoquinoline alkaloid michellamine B and xanthene dye phloxine B.
Mihalyi A; Jamshidi S; Slikas J; Bugg TD
Bioorg Med Chem; 2014 Sep; 22(17):4566-71. PubMed ID: 25127465
[TBL] [Abstract][Full Text] [Related]
12. Bacterial Transferase MraY, a Source of Inspiration towards New Antibiotics.
Fer MJ; Corre LL; Pietrancosta N; Evrard-Todeschi N; Olatunji S; Bouhss A; Calvet-Vitale S; Gravier-Pelletier C
Curr Med Chem; 2018; 25(42):6013-6029. PubMed ID: 29600753
[TBL] [Abstract][Full Text] [Related]
13. Chemical logic of MraY inhibition by antibacterial nucleoside natural products.
Mashalidis EH; Kaeser B; Terasawa Y; Katsuyama A; Kwon DY; Lee K; Hong J; Ichikawa S; Lee SY
Nat Commun; 2019 Jul; 10(1):2917. PubMed ID: 31266949
[TBL] [Abstract][Full Text] [Related]
14. Insights into the Target Interaction of Naturally Occurring Muraymycin Nucleoside Antibiotics.
Koppermann S; Cui Z; Fischer PD; Wang X; Ludwig J; Thorson JS; Van Lanen SG; Ducho C
ChemMedChem; 2018 Apr; 13(8):779-784. PubMed ID: 29438582
[TBL] [Abstract][Full Text] [Related]
15. Antibacterial Nucleoside Natural Products Inhibiting Phospho-MurNAc-Pentapeptide Translocase; Chemistry and Structure-Activity Relationship.
Ichikawa S; Yamaguchi M; Matsuda A
Curr Med Chem; 2015; 22(34):3951-79. PubMed ID: 26282943
[TBL] [Abstract][Full Text] [Related]
16. Structural basis for selective inhibition of antibacterial target MraY, a membrane-bound enzyme involved in peptidoglycan synthesis.
Hering J; Dunevall E; Ek M; Brändén G
Drug Discov Today; 2018 Jul; 23(7):1426-1435. PubMed ID: 29778697
[TBL] [Abstract][Full Text] [Related]
17. Exploring the Active Site of the Antibacterial Target MraY by Modified Tunicamycins.
Hering J; Dunevall E; Snijder A; Eriksson PO; Jackson MA; Hartman TM; Ting R; Chen H; Price NPJ; Brändén G; Ek M
ACS Chem Biol; 2020 Nov; 15(11):2885-2895. PubMed ID: 33164499
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and Medicinal Chemistry of Muraymycins, Nucleoside Antibiotics.
Katsuyama A; Ichikawa S
Chem Pharm Bull (Tokyo); 2018; 66(2):123-131. PubMed ID: 29386462
[TBL] [Abstract][Full Text] [Related]
19. Simplified Novel Muraymycin Analogues; using a Serine Template Strategy for Linking Key Pharmacophores.
Patel B; Kerr RV; Malde AK; Zunk M; Bugg TDH; Grant G; Rudrawar S
ChemMedChem; 2020 Aug; 15(15):1429-1438. PubMed ID: 32476294
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of the nucleoside moiety of liposidomycins: elucidation of the pharmacophore of this family of MraY inhibitors.
Dini C; Collette P; Drochon N; Guillot JC; Lemoine G; Mauvais P; Aszodi J
Bioorg Med Chem Lett; 2000 Aug; 10(16):1839-43. PubMed ID: 10969981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
